Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors

BACKGROUND: ANV419 is a stable antibody–cytokine fusion protein consisting of interleukin-2 (IL-2) fused to an anti-IL-2 monoclonal antibody that sterically hinders binding of IL-2 to the α subunit of its receptor but has selective affinity for the receptor βγ subunits. Thus, ANV419 preferentially s...

Descripción completa

Detalles Bibliográficos
Autores principales: Joerger, Markus, Calvo, Emiliano, Laubli, Heinz, Lopez, Juanita, Alonso, Guzmán, Corral de la Fuente, Elena, Hess, Dagmar, König, David, Sanchez Perez, Vicky, Bucher, Christoph, Jethwa, Sangeeta, Garralda, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668247/
http://dx.doi.org/10.1136/jitc-2023-007784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668247/
http://dx.doi.org/10.1136/jitc-2023-007784

Ejemplares similares